Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

Business Wire January 6, 2022

Personalis to Participate in the 24th Annual Needham Virtual Growth Conference

Business Wire December 28, 2021

Personalis Launches NeXT Personal(TM), A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity

Business Wire December 16, 2021

Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

Business Wire November 18, 2021

Personalis Named to Inc.'s 2021 Best-Led Companies List

Business Wire November 12, 2021

Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Business Wire November 11, 2021

Personalis Reports Third Quarter 2021 Financial Results

Business Wire November 4, 2021

Personalis Announces Updates to NeXT Platform(TM) Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers

Business Wire November 2, 2021

Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform

Business Wire October 26, 2021

Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

Business Wire October 26, 2021

Personalis to Announce Third Quarter Financial Results on November 4, 2021

Business Wire October 21, 2021

Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement

Business Wire October 13, 2021

Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing

Business Wire October 12, 2021

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth

Business Wire September 18, 2021

Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

Business Wire August 26, 2021

Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development

Business Wire August 25, 2021

Personalis Reports Second Quarter 2021 Financial Results

Business Wire August 4, 2021

Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Business Wire August 3, 2021

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS(TM) for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients

Business Wire August 2, 2021

Personalis to Announce Second Quarter Financial Results on August 4, 2021

Business Wire July 21, 2021